131 related articles for article (PubMed ID: 3740675)
21. Alkylating chemotherapeutic agents cyclophosphamide and melphalan cause functional injury to human bone marrow-derived mesenchymal stem cells.
Kemp K; Morse R; Sanders K; Hows J; Donaldson C
Ann Hematol; 2011 Jul; 90(7):777-89. PubMed ID: 21234567
[TBL] [Abstract][Full Text] [Related]
22. Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer.
Chambers SK; Chopyk RL; Chambers JT; Schwartz PE; Duffy TP
Cancer; 1989 Dec; 64(12):2459-61. PubMed ID: 2819655
[TBL] [Abstract][Full Text] [Related]
23. Leukemia after treatment of ovarian cancer with alkylating agents.
Parker LM
N Engl J Med; 1983 Jun; 308(23):1422. PubMed ID: 6843637
[No Abstract] [Full Text] [Related]
24. Twenty-five year outcome of sequential abdominal radiotherapy and melphalan:implications for future management of epithelial carcinoma of the ovary.
Dusenbery KE; Bellairs EE; Potish RA; Twiggs LB; Boente MP
Gynecol Oncol; 2005 Feb; 96(2):307-13. PubMed ID: 15661213
[TBL] [Abstract][Full Text] [Related]
25. Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.
Young RC; Chabner BA; Hubbard SP; Fisher RI; Bender RA; Anderson T; Simon RM; Canellos GP; DeVita VT
N Engl J Med; 1978 Dec; 299(23):1261-6. PubMed ID: 101843
[TBL] [Abstract][Full Text] [Related]
26. Late side effects of chemotherapy in ovarian carcinoma: a cytogenetic, hematologic, and statistical study.
Einhorn N; Eklund G; Franzén S; Lambert B; Lindsten J; Söderhäll S
Cancer; 1982 Jun; 49(11):2234-41. PubMed ID: 7074540
[TBL] [Abstract][Full Text] [Related]
27. Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide.
Haas JF; Kittelmann B; Mehnert WH; Staneczek W; Möhner M; Kaldor JM; Day NE
Br J Cancer; 1987 Feb; 55(2):213-8. PubMed ID: 3814491
[TBL] [Abstract][Full Text] [Related]
28. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin.
Ayash LJ; Elias A; Schwartz G; Wheeler C; Ibrahim J; Teicher BA; Reich E; Warren D; Lynch C; Richardson P; Schnipper L; Frei E; Antman K
J Clin Oncol; 1996 Nov; 14(11):2984-92. PubMed ID: 8918496
[TBL] [Abstract][Full Text] [Related]
29. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
31. Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease.
Pedersen-Bjergaard J; Larsen SO
N Engl J Med; 1982 Oct; 307(16):965-71. PubMed ID: 7110299
[TBL] [Abstract][Full Text] [Related]
32. Melphalan-related leukemia in multiple myeloma.
Wahlin A; Roos G; Rudolphi O; Holm J
Acta Med Scand; 1982 May; 211(3):203-8. PubMed ID: 7080865
[TBL] [Abstract][Full Text] [Related]
33. High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation.
Cesaro S; Meloni G; Messina C; Pillon M; Proglia A; Lanino E; Caniggia M; Bagnulo S; Pession A; Locatelli F;
Bone Marrow Transplant; 2001 Jul; 28(2):131-6. PubMed ID: 11509930
[TBL] [Abstract][Full Text] [Related]
34. Therapy-related leukemia. A report of five patients and a review of the literature.
Advani SH; Doval DC; Gopal R; Nair CN; Kutty PM
Oncology; 1983; 40(4):268-72. PubMed ID: 6346196
[TBL] [Abstract][Full Text] [Related]
35. Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy.
Phillips GL; Shepherd JD; Barnett MJ; Lansdorp PM; Klingemann HG; Spinelli JJ; Nevill TJ; Chan KW; Reece DE
J Clin Oncol; 1991 Oct; 9(10):1880-8. PubMed ID: 1919638
[TBL] [Abstract][Full Text] [Related]
36. Acute myeloid leukemia and other myelopathic disorders following treatment with alkylating agents.
Bennett JM; Moloney WC; Greene MH; Boice JD
Hematol Pathol; 1987; 1(2):99-104. PubMed ID: 3504435
[TBL] [Abstract][Full Text] [Related]
37. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
38. Acute leukemia in rheumatoid arthritis treated with cytotoxic agents.
Seidenfeld AM; Smythe HA; Ogryzlo MA; Urowitz MB; Dotten DA
J Rheumatol; 1976 Sep; 3(3):295-304. PubMed ID: 978665
[TBL] [Abstract][Full Text] [Related]
39. [Plasmocytoma, alkylating agents, and acute myeloid leukemia (author's transl)].
Schmalzl F; Keiser G; Kresbach E; Fritz H; Asamer H; Braunsteiner H
Dtsch Med Wochenschr; 1975 Sep; 100(39):1961-7. PubMed ID: 1057506
[TBL] [Abstract][Full Text] [Related]
40. High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial.
Papadimitriou C; Dafni U; Anagnostopoulos A; Vlachos G; Voulgaris Z; Rodolakis A; Aravantinos G; Bamias A; Bozas G; Kiosses E; Gourgoulis GM; Efstathiou E; Dimopoulos MA
Bone Marrow Transplant; 2008 Mar; 41(6):547-54. PubMed ID: 18026149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
